16.12.2024 • NewsNovo Nordiskinvestment

Novo Nordisk to Build New Production Facility in Odense, Denmark

Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.

The new site will feature a finished production facility and warehouse spanning over 40,000 m2. Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as haemophilia, both now and in the future, Novo Nordisk said.

"The facility will utilize advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines,” commented Henrik Wulff, executive vice president, Product Supply, Quality & IT of Novo Nordisk. “We are proud to build on our heritage in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and talented workforce."

According to Novo Nordisk, construction work has started and is scheduled to be completed in 2027. The investment is expected to create 400 permanent jobs upon completion of the facilities.

The company stated that more than 4,000 new trees will be planted at the site and buildings will be equipped with solar panels to enhance on-site electricity generation. The landscape will be designed by reusing excess soil, wooden materials and other sustainable resources to create lakes, forests and community spaces open to the public.

Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion)...
Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark. │ © Novo Nordisk

Company

Logo:

Novo Nordisk A/S

Novo Allé
2880 Bagsværd
Denmark

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.